The amyloid hypothesis (1) suggests that tau pathology in AD develops downstream from Aβ deposition; therefore if the AMBAR protocol reduced brain Aβ levels, this could have secondarily decreased tau pathology. The gene discussed is MAPT; the disease is Alzheimer disease.